Human C3b/C4b receptor (CR1)

US5856297A · kind A · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• The Brigham and Women's Hospital, Inc. · US
• T Cell Sciences, Inc. · US

Inventors

• Douglas T. Fearon · Baltimore, US
• Lloyd B. Klickstein · Brookline, US
• Winnie W. Wong · Newton, US
• Gerald R. Carson · Belmont, US
• Michael F. Concino · Bolton, US
• Stephen H. Ip · Sudbury, US
• Savvas C. Makrides · Bedford, US
• Henry C. Marsh, Jr. · Reading, US

Key dates

• Filing date: Jun 6, 1995
• Grant date: Jan 5, 1999
• Expiry date: Jun 6, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human complement receptor type 1 (CR1). Nucleic acid molecules encoding full-length CR1 protein and fragments thereof having complement regulatory activity are described, as well as recombinant CR1 protein and polypeptides, vectors for their expression, and cell lines expressing or bearing DNA molecules encoding such proteins and polypeptides, including a soluble CR1 polypeptide consisting of the extracellular 30 short consensus repeat domains of the mature CR1 protein. The nucleic acids and polypeptides described are useful in diagnosis and treatment of disorders involving complement activity and inflammation. Compositions useful in therapeutic applications are also disclosed.